The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Meridian Bioscience Inc

Nasdaq: VIVO
Last

(U.S.) $14.80

Today's change-0.45 -2.95%
Updated July 26 3:44 PM EDT. Delayed by at least 15 minutes.
 

Meridian Bioscience Inc

Nasdaq: VIVO
Last

(U.S.) $14.80

Today's change-0.45 -2.95%
Updated July 26 3:44 PM EDT. Delayed by at least 15 minutes.

Meridian Bioscience Inc crosses below 50-day moving average

Meridian Bioscience Inc is sharply lower today, dropping (U.S.)$0.45 or 2.95% to (U.S.)$14.80 and crossing below its 50-day moving average. Over the last five days, shares have lost 3.58% and are down 16.38% for the last year to date. This security has underperformed the S&P 500 by 41.67% during the last year.

Key company metrics

  • Open(U.S.) $15.30
  • Previous close(U.S.) $15.25
  • High(U.S.) $15.30
  • Low(U.S.) $14.80
  • Bid / Ask(U.S.) $14.80 / (U.S.) $14.85
  • YTD % change-16.38%
  • Volume161,675
  • Average volume (10-day)220,066
  • Average volume (1-month)259,600
  • Average volume (3-month)305,231
  • 52-week range(U.S.) $10.75 to (U.S.) $20.50
  • Beta0.91
  • Trailing P/E21.08×
  • P/E 1 year forward22.52×
  • Forward PEG1.32×
  • Indicated annual dividend(U.S.) $0.50
  • Dividend yield3.38%
  • Trailing EPS(U.S.) $0.70
Updated July 26 3:44 PM EDT. Delayed by at least 15 minutes.
S&P TSX0.12%Sector:HealthcareIndustry:Medical Equipment, Supplies & Distribution
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q2/2017Q1/2017Q4/2016Q3/2016
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedMar 31, 201703/31/2017Dec 31, 201612/31/2016Sep 30, 201609/30/2016Jun 30, 201606/30/2016
Revenue54474751
Total other revenue--------
Total revenue54474751
Gross profit34293033
Total cost of revenue21171718
Total operating expense40373837
Selling / general / administrative15161616
Research & development4344
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)----10
Other operating expenses, total--------
Operating income1410914
Interest income (expense), net non-operating0000
Gain (loss) on sale of assets--------
Other--------
Income before tax1410913
Income after tax9659
Income tax, total5335
Net income9659
Total adjustments to net income--------
Net income before extra. items9659
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items9659
Inc. avail. to common incl. extra. items9659
Diluted net income9659
Dilution adjustment--------
Diluted weighted average shares43434242
Diluted EPS excluding extraordinary itemsvalue per share0.220.150.130.21
Dividends per sharevalue per share0.130.200.200.20
Diluted normalized EPSvalue per share0.220.150.140.21